Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) EPS (Basic) (2017 - 2026)

Cogent Biosciences' EPS (Basic) history spans 10 years, with the latest figure at -$0.53 for Q1 2026.

  • Quarterly EPS (Basic) fell 1.92% to -$0.53 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.17 through Mar 2026, down 10.15% year-over-year, with the annual reading at -$2.16 for FY2025, 11.34% down from the prior year.
  • EPS (Basic) came in at -$0.53 for Q1 2026, up from -$0.61 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.11 in Q4 2022 to a low of -$575.52 in Q2 2023.
  • The 5-year median for EPS (Basic) is -$0.52 (2023), against an average of -$34.32.
  • Year-over-year, EPS (Basic) skyrocketed 117.74% in 2022 and then plummeted 80959.49% in 2023.
  • Cogent Biosciences' EPS (Basic) stood at $0.11 in 2022, then tumbled by 572.73% to -$0.52 in 2023, then grew by 3.85% to -$0.5 in 2024, then fell by 22.0% to -$0.61 in 2025, then grew by 13.11% to -$0.53 in 2026.
  • Per Business Quant, the three most recent readings for COGT's EPS (Basic) are -$0.53 (Q1 2026), -$0.61 (Q4 2025), and -$0.5 (Q3 2025).